Press Release

MONTREAL, November 6, 2017 – Replicor Inc., a privately held biopharmaceutical company targeting a functional cure for patients with chronic HBV infection and HBV / HDV co-infection and the INRS-Institut Armand-Frappier (INRS-IAF) of the Institut National de la Recherche Scientifique (INRS), announced today the formal establishment of a collaboration to identify the mechanisms of HBV subviral particle assembly.

This collaboration, funded by Natural Sciences and Engineering Research Council of Canada (NSERC) and Replicor, establishes a team of scientists whose mission is to discover how HBV subviral particles are formed and released from infected hepatocytes. Led by Dr. Patrick Labonté, this team includes scientists from the INRS-IAF and Replicor and leverages their combined expertise in HBV virology and nucleic acid polymers, a unique antiviral agent that targets SVP assembly / release.

Dr. Andrew Vaillant, CSO of Replicor remarked, “Circulating HBsAg is the most abundant circulating viral protein in chronic HBV or HBV/HDV infection which acts to prevent the immune response (or immunotherapy) from working properly to fight this infection. Virtually all circulating HBsAg is in the form of subviral particles yet we know little to nothing about how these particles are made.” Dr. Vaillant went on to comment, “the initial work from Dr. Labonté’s lab and Replicor scientists has already confirmed that the unique ability of NAP-based combination therapy to achieve functional cure of HBV and HBV / HDV infections is driven by the selective inhibition of the assembly / secretion of subviral particles by NAPs. We expect that improving our understanding of how these subviral particles are formed will lead to the identification of the molecular target of NAPs driving their unique antiviral properties.”

About Replicor
Replicor is a privately held biopharmaceutical company with the most advanced animal and human clinical data in the development of a functional cure for HBV and HDV. The company is dedicated to accelerating the development of an effective treatment for patients with HBV and HBV/HDV co-infection. For further information about Replicor please visit our website at www.replicor.com.

Media Contact:
Natacha Dorget
ndorget@replicor.com
(514) 733-1998